Last updated: March 9, 2026
What is NDC 00472-0380?
NDC 00472-0380 refers to Erelzi (etanercept-szzs), a biosimilar of Enbrel (etanercept), used for treating autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. It was approved by the FDA in August 2018 and licensed for commercial use.
Market Landscape
Competition and Market Positioning
Erelzi is part of the biosimilar segment targeting established biologics, specifically following the expiration of United Therapeutics' Enbrel patents around 2028. The biosimilar landscape for etanercept includes multiple competitors such as:
- Amgen’s Amjevita (adalimumab-atto)
- Sandoz’s Erelzi (etanercept-szzs)
- Biogen’s Benepali (etanercept) in some markets outside the US.
Key Market Drivers
- Increasing prevalence of autoimmune diseases globally.
- Growing demand to reduce biologics costs.
- Favorable reimbursement policies in the US and Europe for biosimilars.
- Patent exclusivity expirations for original biologics pushing biosimilar adoption.
Market Size and Growth
Estimated US biologic therapies market (2018-2025) for rheumatoid arthritis and psoriasis base:
| Year |
Market Size (USD billion) |
CAGR |
| 2018 |
28.9 |
— |
| 2022 |
40.2 |
10.5% |
| 2025 |
55.8 |
12.0% |
Biosimilars like Erelzi are expected to comprise a growing share of this market, reaching approximately 20%-25% by 2025.
Adoption Factors
- Physicians' acceptance of biosimilars.
- Cost savings for healthcare systems.
- Payer policies favoring biosimilar substitution.
- Patient access improvements.
Pricing Dynamics
Current Pricing of Erelzi
- In the US, list price per syringe: approximately USD 1,300–1,500.
- Reimbursement rates, negotiated discounts, and patient copay assistance vary. Actual transaction prices are often 30-50% lower than list prices, reflecting discounts and rebates.
Comparative Pricing
| Product |
List Price (USD) |
Estimated Net Price (USD) |
| Erelzi |
1,400 |
700–1,000 |
| Enbrel |
2,700 |
1,600–2,100 |
Note: Biosimilars typically price 15%-35% lower than reference biologics initially, followed by further reductions with increased market penetration.
Price Trends and Projections
- Price reductions of 10%-20% per year are anticipated in biosimilar segments as competition intensifies.
- Entry of multiple biosimilars may further pressure prices.
- Reimbursement shifts in favor of biosimilars could lead to simplified access and increased volume sales.
Forecast for 2025
| Scenario |
Price Range (USD) |
Market Share |
Revenue Projection (USD million) |
| Conservative |
800–900 |
10% |
250–300 |
| Moderate |
700–800 |
15% |
400–500 |
| Aggressive |
600–700 |
20% |
600–700 |
Assuming continued biosimilar uptake, revenue for Erelzi could reach USD 300-700 million globally by 2025.
Regulatory and Policy Impact
- US biosimilar interchangeability policies could enhance substitution at pharmacy level.
- European markets show rapid biosimilar adoption, with savings reaching 30-40% for biologic therapies.
- Patent litigations or exclusivity periods influence market entry timing.
Conclusion
Erelzi's market will expand via biosimilar adoption accelerated by cost pressure, policy shifts, and increased disease prevalence. Its pricing will decline, with revenues highly sensitive to physician acceptance and healthcare system policies. Near-term revenue estimates hover around USD 300-700 million globally by 2025, contingent on competitive dynamics.
Key Takeaways
- Erelzi (NDC 00472-0380) is a biosimilar of Enbrel approved in 2018.
- Biosimilar market share for etanercept is projected to reach 20%-25% by 2025.
- US list price: approximately USD 1,400 per syringe; net prices below USD 1,000.
- Revenue potential ranges from USD 300-700 million, depending on market penetration.
- Price reductions of 10%-20% annually are expected as market competition increases.
FAQs
1. How does Erelzi compare to other biosimilars for etanercept?
Erelzi's price and market penetration are similar to competitors like Benepali, with slight differences in market availability and payer acceptance.
2. What are the main barriers to biosimilar adoption?
Physician reluctance, brand loyalty, patent litigation, and reimbursement policies can delay biosimilar uptake.
3. How will policy changes affect biosimilar prices?
Policy shifts favoring substitution at pharmacy or formulary levels decrease prices further due to increased competition.
4. When will Erelzi's revenue likely peak?
If market penetration reaches 20%-25% globally by 2025, revenues could plateau or slightly decline afterward due to further price cuts.
5. Are there exclusivity periods that could delay Erelzi’s market growth?
No. Biosimilar exclusivity in the US is limited, but patent disputes can delay market entry in specific regions.
References
[1] U.S. Food and Drug Administration. (2018). Erelzi approval letter. Retrieved from https://www.fda.gov
[2] IQVIA Institute. (2022). The Global Use of Biosimilars. IQVIA.
[3] EvaluatePharma. (2022). World Market Insight: Biologics & Biosimilars.
[4] Congressional Budget Office. (2020). Biosimilars and Their Impact on Prices.
[5] European Medicines Agency. (2022). Biosimilar medicines in the EU.
